Compare · IOVA vs MRKR

IOVA vs MRKR

Side-by-side comparison of Iovance Biotherapeutics Inc. (IOVA) and Marker Therapeutics Inc. (MRKR): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both companies sit in the Health Care sector. IOVA focuses on Biotechnology: Biological Products (No Diagnostic Substances), while MRKR focuses on Biotechnology: Pharmaceutical Preparations.
  • IOVA is the larger of the two at $3.19B, about 175.7x MRKR ($18.2M).
  • IOVA has been more active in the news (15 items in the past 4 weeks vs 3 for MRKR).
  • IOVA has more recent analyst coverage (21 ratings vs 2 for MRKR).
MetricIOVAMRKR
Company
Iovance Biotherapeutics Inc.
Marker Therapeutics Inc.
Price
-
-
Market cap
$3.19B
$18.2M
1M return
-
-
1Y return
-
-
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NASDAQ
IPO
News (4w)
15
3
Recent ratings
21
2
IOVA

Iovance Biotherapeutics Inc.

Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

MRKR

Marker Therapeutics Inc.

Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA-specific T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company's MultiTAA-specific T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial for the treatment of breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. Marker Therapeutics, Inc. is headquartered in Houston, Texas.

Latest IOVA

Latest MRKR